Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03762265
Registration number
NCT03762265
Ethics application status
Date submitted
29/11/2018
Date registered
3/12/2018
Titles & IDs
Public title
A Study of PRN1008 in Patients With Pemphigus
Query!
Scientific title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor Rilzabrutinib (PRN1008) in Moderate to Severe Pemphigus
Query!
Secondary ID [1]
0
0
PRN1008-012
Query!
Secondary ID [2]
0
0
EFC17092
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pemphigus
0
0
Query!
Condition category
Condition code
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Autoimmune diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Rilzabrutinib
Treatment: Drugs - Placebo
Placebo comparator: Placebo Then Rilzabrutinib - In BT period, participants received placebo orally twice daily (BID) up to 37 weeks along with sponsor-provided corticosteroids (CS). After at least two weeks of control of disease activity (CDA; no new lesions and established lesions begin to heal), based on protocol-specified clinical criteria, investigators could decrease the CS dose to a minimum of 5 milligrams (mg) prednisone/prednisolone per day from Week 29 to Week 37. Post completion of BT period, eligible participants received rilzabrutinib 400 mg BID up to Week 61 in OLE period and those who were eligible after OLE period completion, continued the same treatment until Week 109 in LTE period according to protocol-specified criteria.
Experimental: Rilzabrutinib Then Rilzabrutinib - In BT period, participants received rilzabrutinib 400 mg orally BID up to 37 weeks along with sponsor-provided CS. After at least two weeks of CDA (no new lesions and established lesions begin to heal), based on protocol-specified clinical criteria, investigators could decrease the CS dose to a minimum of 5 mg prednisone/prednisolone per day from Week 29 to Week 37. Post completion of BT period, eligible participants received rilzabrutinib 400 mg BID up to Week 61 in OLE period and those who were eligible after OLE period completion, continued the same treatment until Week 109 in LTE period according to protocol-specified criteria.
Treatment: Drugs: Rilzabrutinib
Pharmaceutical form: Tablet Route of administration: Oral
Treatment: Drugs: Placebo
Pharmaceutical form: Tablet Route of administration: Oral
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Who Achieved Complete Remission (CR) With a Corticosteroids Dose of Less Than or Equal to (<=) 10 mg/Day From Week 29 to Week 37: Pemphigus Vulgaris Participants in Modified Intent-to-Treat (PV mITT) Population
Query!
Assessment method [1]
0
0
Complete remission was defined as absence of new and established lesions and was intended to mean "no disease activity" for 2 consecutive weeks, with Pemphigus Disease Area Index (PDAI) activity score =0 and CS dose \<=10 mg. PDAI score weighted for number and size of lesions with score of 0 (absent) to 10 given for skin (12 body locations), scalp and mucous membrane showing disease activity (erosions/blisters or new erythema). PDAI total score ranged from 0 to 250 points representing disease activity (120 points for skin activity; 10 points for scalp activity; 120 points for mucosal activity). Higher score indicated more disease activity. In this outcome measure (OM), percentage of participants who achieved CR while on a daily corticosteroids dose of \<=10 mg/day were reported.
Query!
Timepoint [1]
0
0
From Week 29 to Week 37
Query!
Primary outcome [2]
0
0
Percentage of Participants Who Achieved Complete Remission With a Corticosteroids Dose of <=10 mg/Day From Week 29 to Week 37: Modified Intent-to-Treat (mITT) Population
Query!
Assessment method [2]
0
0
Complete remission was defined as absence of new and established lesions and was intended to mean "no disease activity" for 2 consecutive weeks, with PDAI activity score =0 and CS dose \<=10 mg. PDAI score weighted for number and size of lesions with score of 0 (absent) to 10 given for skin (12 body locations), scalp and mucous membrane showing disease activity (erosions/blisters or new erythema). PDAI total score ranged from 0 to 250 points representing disease activity (120 points for skin activity; 10 points for scalp activity; 120 points for mucosal activity). Higher score indicated more disease activity. In this OM, percentage of participants who achieved CR while on a daily corticosteroids dose of \<=10 mg/day were reported.
Query!
Timepoint [2]
0
0
From Week 29 to Week 37
Query!
Secondary outcome [1]
0
0
Cumulative Oral Corticosteroid Dose From Baseline to Week 37: PV mITT Population
Query!
Assessment method [1]
0
0
The cumulative dose (in milligrams) of sponsor-provided oral CS (prednisone or prednisolone) received by the participants during the BT period was calculated from Baseline to Week 37 and is reported in this OM.
Query!
Timepoint [1]
0
0
Baseline to Week 37
Query!
Secondary outcome [2]
0
0
Cumulative Oral Corticosteroid Dose From Baseline to Week 37: mITT Population
Query!
Assessment method [2]
0
0
The cumulative dose (in milligrams) of sponsor-provided oral CS (prednisone or prednisolone) received by the participants during the BT period was calculated from Baseline to Week 37 and is reported in this OM.
Query!
Timepoint [2]
0
0
Baseline to Week 37
Query!
Secondary outcome [3]
0
0
Cumulative Duration of Complete Remission With a Corticosteroids Dose <=10 mg/Day From Baseline to Week 37: PV mITT Population
Query!
Assessment method [3]
0
0
Cumulative duration (in days) of CR post first CS dose of \<= 10 mg/day from Baseline to Week 37 was analyzed with a zero-inflated negative binomial model with terms of treatment group and disease history, and an offset based on the number of days on blinded treatment period and were reported in this OM. Complete remission was defined as the absence of new and established lesions and was intended to mean "no disease activity".
Query!
Timepoint [3]
0
0
Baseline to Week 37
Query!
Secondary outcome [4]
0
0
Cumulative Duration of Complete Remission With a Corticosteroids Dose <=10 mg/Day From Baseline to Week 37: mITT Population
Query!
Assessment method [4]
0
0
Cumulative duration (in days) of CR post first CS dose of \<= 10 mg/day from Baseline to Week 37 was analyzed with a zero-inflated negative binomial model with terms of treatment group and disease history, and an offset based on the number of days on blinded treatment period and were reported in this OM. Complete remission was defined as the absence of new and established lesions and was intended to mean "no disease activity".
Query!
Timepoint [4]
0
0
Baseline to Week 37
Query!
Secondary outcome [5]
0
0
Time to First Complete Remission With a Corticosteroids Dose <=10 mg/Day From Baseline to Week 37: PV mITT Population
Query!
Assessment method [5]
0
0
Time to first CR was the time (in days) to achieve CR while on CS dose of \<=10 mg/day. Complete remission was defined as the absence of new and established lesions to the "no disease activity". Kaplan-Meier method was used for the analysis.
Query!
Timepoint [5]
0
0
Baseline to Week 37
Query!
Secondary outcome [6]
0
0
Time to First Complete Remission With a Corticosteroids Dose <=10 mg/Day From Baseline to Week 37: mITT Population
Query!
Assessment method [6]
0
0
Time to first CR was the time (in days) to achieve CR while on CS dose of \<=10 mg/day. Complete remission was defined as the absence of new and established lesions to the "no disease activity". Kaplan-Meier method was used for the analysis.
Query!
Timepoint [6]
0
0
Baseline to Week 37
Query!
Secondary outcome [7]
0
0
Percentage of Participants Who Achieved Complete Remission With a Corticosteroids Dose of <=5 mg/Day From Week 29 to Week 37: PV mITT Population
Query!
Assessment method [7]
0
0
Complete remission was defined as the absence of new and established lesions and was intended to mean "no disease activity". In this OM, percentage of participants who achieved CR while on a daily corticosteroids dose of \<=5 mg/day were reported.
Query!
Timepoint [7]
0
0
From Week 29 to Week 37
Query!
Secondary outcome [8]
0
0
Percentage of Participants Who Achieved Complete Remission With a Corticosteroids Dose of <=5 mg/Day From Week 29 to Week 37: mITT Population
Query!
Assessment method [8]
0
0
Complete remission was defined as the absence of new and established lesions and was intended to mean "no disease activity". In this OM, percentage of participants who achieved CR while on a daily corticosteroids dose of \<=5 mg/day were reported.
Query!
Timepoint [8]
0
0
From Week 29 to Week 37
Query!
Secondary outcome [9]
0
0
Percentage of Participants Who Had Pemphigus Disease Area Index (PDAI) Score <3 With a Corticosteroids Dose <=10 mg/Day From Week 29 to Week 37: PV mITT Population
Query!
Assessment method [9]
0
0
PDAI is specific cutaneous and mucosal disease activity assessment performed by investigator based on evaluation of lesions in well-defined anatomical locations. The score weighted for the number and size of lesions with score of 0 (absent) to 10 given for skin (12 body locations), scalp and mucous membrane showing disease activity (erosions/blisters or new erythema). Thus, PDAI total activity score ranged from 0 to 250 points representing disease activity (120 points for skin activity; 10 points for scalp activity; 120 points for mucosal activity). Higher score indicated more disease activity. In this OM, participants with PDAI score \<3 while on a CS dose of \<=10 mg/day were reported.
Query!
Timepoint [9]
0
0
From Week 29 to Week 37
Query!
Secondary outcome [10]
0
0
Percentage of Participants Who Had Pemphigus Disease Area Index Score <3 With a Corticosteroids Dose <=10 mg/Day From Week 29 to Week 37: mITT Population
Query!
Assessment method [10]
0
0
PDAI is specific cutaneous and mucosal disease activity assessment performed by investigator based on evaluation of lesions in well-defined anatomical locations. The score weighted for the number and size of lesions with score of 0 (absent) to 10 given for skin (12 body locations), scalp and mucous membrane showing disease activity (erosions/blisters or new erythema). Thus, PDAI total activity score ranged from 0 to 250 points representing disease activity (120 points for skin activity; 10 points for scalp activity; 120 points for mucosal activity). Higher score indicated more disease activity. In this OM, participants with PDAI score \<3 while on a CS dose of \<=10 mg/day were reported.
Query!
Timepoint [10]
0
0
From Week 29 to Week 37
Query!
Secondary outcome [11]
0
0
Cumulative Duration of Complete Remission With a Corticosteroids Dose <=10 mg/Day From Baseline to Weeks 61 and 109: PV mITT Population
Query!
Assessment method [11]
0
0
Cumulative duration (in days) of CR post all doses of CS \<=10 mg/day during Baseline to Week 61 and Baseline to Week 109 were reported in this OM. Complete remission was defined as the absence of new and established lesions to the "no disease activity".
Query!
Timepoint [11]
0
0
Baseline to Week 61 and Baseline to Week 109
Query!
Secondary outcome [12]
0
0
Cumulative Duration of Complete Remission With a Corticosteroids Dose <=10 mg/Day From Baseline to Weeks 61 and 109: mITT Population
Query!
Assessment method [12]
0
0
Cumulative duration (in days) of CR post all doses of CS \<=10 mg/day during Baseline to Week 61 and Baseline to Week 109 were reported in this OM. Complete remission was defined as the absence of new and established lesions to the "no disease activity".
Query!
Timepoint [12]
0
0
Baseline to Weeks 61 and Baseline to Week 109
Query!
Secondary outcome [13]
0
0
Cumulative Duration of Complete Remission With a Corticosteroids Dose = 0 mg/Day From Baseline to Weeks 61 and 109: PV mITT Population
Query!
Assessment method [13]
0
0
Cumulative duration (in days) of CR post all doses of CS =0 mg/day during Baseline to Week 61 and Baseline to Week 109 were reported in this OM. Complete remission was defined as the absence of new and established lesions to the "no disease activity".
Query!
Timepoint [13]
0
0
Baseline to Week 61 and Baseline to Week 109
Query!
Secondary outcome [14]
0
0
Cumulative Duration of Complete Remission With a Corticosteroids Dose = 0 mg/Day From Baseline to Weeks 61 and 109: mITT Population
Query!
Assessment method [14]
0
0
Cumulative duration (in days) of CR post all doses of CS dose = 0 mg/day during Baseline to Week 61 and Baseline to Week 109 were reported in this OM. Complete remission was defined as the absence of new and established lesions to the "no disease activity".
Query!
Timepoint [14]
0
0
Baseline to Week 61 and Baseline to Week 109
Query!
Secondary outcome [15]
0
0
Glucocorticoid Toxicity Index (GTI) - Cumulative Worsening Score (CWS) and Aggregate Improvement Score (AIS) at Week 37: PV mITT Population
Query!
Assessment method [15]
0
0
GTI assessed glucocorticoid (GC) related morbidity and GC-sparing ability of other therapies; composed of 2 components: Composite GTI and specific list. Composite GTI had 9 domains and specific list had 23 items (11 domains), used as complementary tool to C-GTI. Composite GTI score:sum of 9 domain-specific scores at each visit and cumulative GTI score:sum of composite GTI scores across each visit. 2 cumulative GTI scores: CWS and AIS at Week 37 reported in this OM. CWS assessed cumulative GC toxicity regardless of whether toxicity had lasting effects/was transient. AIS assessed new therapy effectiveness in decreasing any Baseline GC toxicity over time. CWS composite score range: 0 to 439 and AIS composite score range: -346 to 439. In CWS and AIS, minimum score=least toxicity and maximum score=most toxicity. Least square (LS) mean and standard error (SE) from analysis of covariance model using treatment, disease history as fixed effects and Baseline GTI score and CS dose as covariates.
Query!
Timepoint [15]
0
0
At Week 37
Query!
Secondary outcome [16]
0
0
Glucocorticoid Toxicity Index - Cumulative Worsening Score and Aggregate Improvement Score at Week 37: mITT Population
Query!
Assessment method [16]
0
0
GTI assessed GC related morbidity and GC-sparing ability of other therapies; composed of 2 components: Composite GTI and specific list. Composite GTI contained 9 domains and specific list contained of 23 items (11 domains), used as complementary tool to C-GTI. Composite GTI score: sum of 9 domain-specific scores at each visit and cumulative GTI score: sum of composite GTI scores across each visit. Two cumulative GTI scores: CWS and AIS at Week 37 were reported in this OM. CWS assessed cumulative GC toxicity regardless of whether toxicity had lasting effects/was transient. AIS assessed new therapy effectiveness in decreasing any Baseline GC toxicity over time. CWS composite score ranged from 0 to 439 and AIS composite score ranged from -346 to 439. For CWS and AIS, minimum score = least toxicity and maximum score = most toxicity. LS mean and SE from analysis of covariance model using treatment, disease history as fixed effects and Baseline GTI score and CS dose as covariates.
Query!
Timepoint [16]
0
0
At Week 37
Query!
Secondary outcome [17]
0
0
Change From Baseline in Pemphigus Disease Area Index Score at Weeks 5, 13, 25, 37, 61, and 109: PV mITT Population
Query!
Assessment method [17]
0
0
PDAI is specific cutaneous and mucosal disease activity assessment performed by investigator based on evaluation of lesions in well-defined anatomical locations. The score weighted for the number and size of lesions with score of 0 (absent) to 10 given for skin (12 body locations), scalp and mucous membrane showing disease activity (erosions/blisters or new erythema). Thus, PDAI total activity score ranged from 0 to 250 points representing disease activity (120 points for skin activity; 10 points for scalp activity; 120 points for mucosal activity). Higher score indicated more disease activity. PDAI activity score was measured independently of the CS dose administered in the participants.
Query!
Timepoint [17]
0
0
Baseline, Weeks 5, 13, 25, 37, 61, and 109
Query!
Secondary outcome [18]
0
0
Change From Baseline in Pemphigus Disease Area Index Score at Weeks 5, 13, 25, 37, 61, and 109: mITT Population
Query!
Assessment method [18]
0
0
PDAI is specific cutaneous and mucosal disease activity assessment performed by investigator based on evaluation of lesions in well-defined anatomical locations. The score weighted for the number and size of lesions with score of 0 (absent) to 10 given for skin (12 body locations), scalp and mucous membrane showing disease activity (erosions/blisters or new erythema). Thus, PDAI total activity score ranged from 0 to 250 points representing disease activity (120 points for skin activity; 10 points for scalp activity; 120 points for mucosal activity). Higher score indicated more disease activity. PDAI activity score was measured independently of the CS dose administered in the participants.
Query!
Timepoint [18]
0
0
Baseline, Weeks 5, 13, 25, 37, 61, and 109
Query!
Secondary outcome [19]
0
0
Change From Baseline in Autoimmune Bullous Disease Quality of Life (ABQOL) Score at Weeks 5, 13, 25, 37, 61, and 109: PV mITT Population
Query!
Assessment method [19]
0
0
ABQOL, a 17-item questionnaire is a valid and reliable tool to assess quality of life in participants with autoimmune blistering diseases. Each question score ranged from 0 to 3 points, 0 = never, 1 = occasionally, 2 = sometimes and 3 = all the time, where higher score = poor QOL. The total ABQoL score was calculated by summing the score of each question and it ranged from 0 to 51, where higher score = more QOL impairment.
Query!
Timepoint [19]
0
0
Baseline, Weeks 5, 13, 25, 37, 61, and 109
Query!
Secondary outcome [20]
0
0
Change From Baseline in Autoimmune Bullous Disease Quality of Life Score at Weeks 5, 13, 25, 37, 61, and 109: mITT Population
Query!
Assessment method [20]
0
0
ABQOL, a 17-item questionnaire is a valid and reliable tool to assess quality of life in participants with autoimmune blistering diseases. Each question score ranged from 0 to 3 points, 0 = never, 1 = occasionally, 2 = sometimes and 3 = all the time, where higher score = poor QOL. The total ABQoL score was calculated by summing the score of each question and it ranged from 0 to 51, where higher score = more QOL impairment.
Query!
Timepoint [20]
0
0
Baseline, Weeks 5, 13, 25, 37, 61, and 109
Query!
Secondary outcome [21]
0
0
Percentage of Participants With Autoimmune Bullous Disease Quality of Life Score of Zero at Weeks 5, 13, 25, 37, 61, and 109: PV mITT Population
Query!
Assessment method [21]
0
0
ABQOL, a 17-item questionnaire is a valid and reliable tool to assess quality of life in participants with autoimmune blistering diseases. Each question score ranged from 0 to 3 points, 0 = never, 1 = occasionally, 2 = sometimes and 3 = all the time, where higher score = poor QOL. The total ABQoL score was calculated by summing the score of each question and it ranged from 0 to 51, where higher score = more QOL impairment. Percentage of participants with ABQOL score of '0' were reported in this outcome measure.
Query!
Timepoint [21]
0
0
At Weeks 5, 13, 25, 37, 61, and 109
Query!
Secondary outcome [22]
0
0
Percentage of Participants With Autoimmune Bullous Disease Quality of Life Score of Zero at Weeks 5, 13, 25, 37, 61, and 109: mITT Population
Query!
Assessment method [22]
0
0
ABQOL, a 17-item questionnaire is a valid and reliable tool to assess quality of life in participants with autoimmune blistering diseases. Each question score ranged from 0 to 3 points, 0 = never, 1 = occasionally, 2 = sometimes and 3 = all the time, where higher score = poor QOL. The total ABQoL score was calculated by summing the score of each question and it ranged from 0 to 51, where higher score = more QOL impairment. Percentage of participants with ABQOL score of '0' were reported in this outcome measure.
Query!
Timepoint [22]
0
0
At Weeks 5, 13, 25, 37, 61, and 109
Query!
Secondary outcome [23]
0
0
Change From Baseline in the European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Score: Visual Analogue Scale (VAS) Scores at Weeks 5, 13, 25, 37, 61, and 109
Query!
Assessment method [23]
0
0
EQ-5D-5L: standardized measure of health status that provides general assessment of health and wellbeing. EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS scale ranging from 0 to 100, where 0=worst imaginable health state and 100=best imaginable health state, where higher states indicated better outcomes.
Query!
Timepoint [23]
0
0
Baseline, Weeks 5, 13, 25, 37, 61, and 109
Query!
Secondary outcome [24]
0
0
Change From Baseline in the European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels Score: Individual Dimension at Weeks 5, 13, 25, 37, 61, and 109
Query!
Assessment method [24]
0
0
EQ-5D-5L: standardized measure of health status that provides general assessment of health and wellbeing. The EQ-5D descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has a 5-level response: no problems, slight problems, moderate problems, severe problems, and extreme problems. Response options are measured with a 5-point Likert scale (for the 5L version). The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state and lower score indicate worse health state.
Query!
Timepoint [24]
0
0
Baseline, Weeks 5, 13, 25, 37, 61, and 109
Query!
Secondary outcome [25]
0
0
Time to First Complete Remission With a Corticosteroids Dose <=10 mg/Day From Baseline to Weeks 61 and 109
Query!
Assessment method [25]
0
0
Time to first CR was the time (in days) to achieve CR while on a CS dose of \<=10 mg/day from Baseline to Week 61 and from Baseline to Week 109. Complete remission was defined as absence of new and established lesions to the "no disease activity".
Query!
Timepoint [25]
0
0
Baseline to Week 61 and Baseline to Week 109
Query!
Secondary outcome [26]
0
0
Total Number of Disease Relapses/Flares From Initial Control of Disease Activity (CDA) to Week 37: PV mITT Population
Query!
Assessment method [26]
0
0
Total Number of Disease Relapses/Flares which occurred from initial CDA to Week 37 were reported. CDA was defined as disappearance of new lesions cease to form and established lesions begin to heal. Relapse/flare was defined by the appearance of 3 or more new lesions after CDA and within a month that do not heal spontaneously within 1 week, or by the extension of established lesions, in a participant who had achieved CDA.
Query!
Timepoint [26]
0
0
From initial CDA up to Week 37 (i.e., during any time from Baseline up to Week 37)
Query!
Secondary outcome [27]
0
0
Total Number of Disease Relapses/Flares From Initial Control of Disease Activity to Week 37: mITT Population
Query!
Assessment method [27]
0
0
Total Number of Disease Relapses/Flares which occurred from initial CDA to Week 37 were reported. CDA was defined as disappearance of new lesions cease to form and established lesions begin to heal. Relapse/flare was defined by the appearance of 3 or more new lesions after CDA and within a month that do not heal spontaneously within 1 week, or by the extension of established lesions, in a participant who had achieved CDA.
Query!
Timepoint [27]
0
0
From initial CDA up to Week 37 (i.e., during any time from Baseline up to Week 37)
Query!
Secondary outcome [28]
0
0
Time to Initial Relapse/Flare From Initial Control of Disease Activity to Week 37: PV mITT Population
Query!
Assessment method [28]
0
0
Time duration (in days) from the time of initial relapse/flare which occurred from initial CDA up to Week 37 were reported in this OM. CDA was defined as the visit at which new lesions cease to form and established lesions begin to heal. Relapse/flare was defined by the appearance of 3 or more new lesions after CDA and within a month that do not heal spontaneously within 1 week, or by the extension of established lesions, in a participant who had achieved CDA. Kaplan-Meier method was used for the analysis.
Query!
Timepoint [28]
0
0
From initial CDA up to Week 37 (i.e., during any time from Baseline up to Week 37)
Query!
Secondary outcome [29]
0
0
Time to Initial Relapse/Flare From Initial Control of Disease Activity to Week 37: mITT Population
Query!
Assessment method [29]
0
0
Time duration (in days) from the time of initial relapse/flare which occurred from initial CDA up to Week 37 were reported in this OM. CDA was defined as the visit at which new lesions cease to form and established lesions begin to heal. Relapse/flare was defined by the appearance of 3 or more new lesions after CDA and within a month that do not heal spontaneously within 1 week, or by the extension of established lesions, in a participant who had achieved CDA. Kaplan-Meier method was used for the analysis.
Query!
Timepoint [29]
0
0
From initial CDA up to Week 37 (i.e., during any time from Baseline up to Week 37)
Query!
Secondary outcome [30]
0
0
Percentage of Participants With 3 or More New Lesions Within 1 Month That do Not Heal Spontaneously Within 1 Week, or With Extension of Established Lesions at Week 37: PV mITT Population
Query!
Assessment method [30]
0
0
Percentage of Participants With 3 or More New Lesions Within past 1 month that do not heal spontaneously within past 1 week, or with extension of established lesions, were assessed at Week 37 and reported in this OM.
Query!
Timepoint [30]
0
0
At Week 37
Query!
Secondary outcome [31]
0
0
Percentage of Participants With 3 or More New Lesions Within 1 Month That do Not Heal Spontaneously Within 1 Week, or With Extension of Established Lesions at Week 37: mITT Population
Query!
Assessment method [31]
0
0
Percentage of participants with 3 or more new lesions within past 1 month that do not heal spontaneously within past 1 week, or with extension of established lesions, were assessed at Week 37 and reported in this OM.
Query!
Timepoint [31]
0
0
At Week 37
Query!
Secondary outcome [32]
0
0
Percentage of Participants With at Least One Disease Relapse/Flare From Initial Control of Disease Activity to Week 37: PV mITT Population
Query!
Assessment method [32]
0
0
CDA was defined as the visit at which new lesions cease to form and established lesions begin to heal. Disease relapse/flare was defined by the appearance of 3 or more new lesions after CDA and within a month that do not heal spontaneously within 1 week, or by the extension of established lesions, in a participant who had achieved CDA. Percentages were calculated based on number of participants assessed (i.e. participants achieved CDA) in each treatment group. Percentage of participants with at least one disease relapse/flare from Initial CDA to Week 37 were reported in this OM.
Query!
Timepoint [32]
0
0
From initial CDA up to Week 37 (i.e., during any time from Baseline up to Week 37)
Query!
Secondary outcome [33]
0
0
Percentage of Participants With at Least One Disease Relapse/Flare From Initial Control of Disease Activity to Week 37: mITT Population
Query!
Assessment method [33]
0
0
CDA was defined as the visit at which new lesions cease to form and established lesions begin to heal. Disease relapse/flare was defined by the appearance of 3 or more new lesions after CDA and within a month that do not heal spontaneously within 1 week, or by the extension of established lesions, in a participant who had achieved CDA. Percentages were calculated based on number of participants assessed (i.e. participants achieved CDA) in each treatment group. Percentage of participants with at least one disease relapse/flare from Initial CDA to Week 37 were reported in this OM.
Query!
Timepoint [33]
0
0
From initial CDA up to Week 37 (i.e., during any time from Baseline up to Week 37)
Query!
Secondary outcome [34]
0
0
Cumulative Duration of Complete Remission With a Corticosteroids Dose <=10 mg/Day From Week 37 to Week 61: PV mITT Population
Query!
Assessment method [34]
0
0
Cumulative duration (in days) of CR post first dose of CS \<=10 mg/day from Week 37 to Week 61 were reported in this OM. Complete remission was defined as the absence of new and established lesions and was intended to mean "no disease activity".
Query!
Timepoint [34]
0
0
From Week 37 to Week 61
Query!
Secondary outcome [35]
0
0
Cumulative Duration of Complete Remission With a Corticosteroids Dose <=10 mg/Day From Week 37 to Week 61: mITT Population
Query!
Assessment method [35]
0
0
Cumulative duration (in days) of CR post first dose of CS \<=10 mg/day from Week 37 to Week 61 were reported in this OM. Complete remission was defined as the absence of new and established lesions and was intended to mean "no disease activity".
Query!
Timepoint [35]
0
0
From Week 37 to Week 61
Query!
Secondary outcome [36]
0
0
Cumulative Duration of Complete Remission With a Corticosteroids Dose = 0 mg/Day From Week 37 to Week 61: PV mITT Population
Query!
Assessment method [36]
0
0
Cumulative duration (in days) of CR post first dose of CS = 0 mg/day from Week 37 to Week 61 were reported in this OM. Complete remission was defined as the absence of new and established lesions and was intended to mean "no disease activity".
Query!
Timepoint [36]
0
0
From Week 37 to Week 61
Query!
Secondary outcome [37]
0
0
Cumulative Duration of Complete Remission With a Corticosteroids Dose = 0 mg/Day From Week 37 to Week 61: mITT Population
Query!
Assessment method [37]
0
0
Cumulative duration (in days) of CR post first dose of CS = 0 mg/day from Week 37 to Week 61 were reported in this OM. Complete remission was defined as the absence of new and established lesions and was intended to mean "no disease activity".
Query!
Timepoint [37]
0
0
From Week 37 to Week 61
Query!
Secondary outcome [38]
0
0
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
Query!
Assessment method [38]
0
0
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and does not necessarily had to have a causal relationship with the treatment. Serious AEs (SAEs) were any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were the AEs that developed or worsened or became serious after the administration of first dose of study drug in each period.
Query!
Timepoint [38]
0
0
BT Period: From Day 1 of Week 1 to Week 37, OLE Period: from Week 37 to Week 61 and LTE Period: from Week 61 up to 4 weeks after the last dose at Week 109 (i.e., up to Week 113)
Query!
Secondary outcome [39]
0
0
Pharmacokinetics (PK): Plasma Concentration of Rilzabrutinib
Query!
Assessment method [39]
0
0
Data for this OM was not planned to be collected and analyzed for placebo arm of the study.
Query!
Timepoint [39]
0
0
Pre-dose and 2 hours post-dose on Day 1
Query!
Secondary outcome [40]
0
0
Pharmacodynamics (PD): Change From Baseline in Antibody Levels - Anti-desmoglein 1 (Anti-dsg 1) and Anti-desmoglein 3 (Anti-dsg 3) at Weeks 13, 25, 37, 49, 61, 73, 85, 97, and 109: PV mITT Population
Query!
Assessment method [40]
0
0
Anti-dsg1 and anti-dsg3 autoantibody levels was assessed by enzyme-linked immunosorbent assay (ELISA) method.
Query!
Timepoint [40]
0
0
Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, and 109
Query!
Secondary outcome [41]
0
0
Pharmacodynamics: Change From Baseline in Antibody Levels - Anti-desmoglein 1 (Anti-dsg 1) and Anti-desmoglein 3 (Anti-dsg 3) at Weeks 13, 25, 37, 49, 61, 73, 85, 97 and 109: mITT Population
Query!
Assessment method [41]
0
0
Anti-dsg1 and anti-dsg3 autoantibody levels was assessed by ELISA method.
Query!
Timepoint [41]
0
0
Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, and 109
Query!
Eligibility
Key inclusion criteria
* Male or female participants, aged 18 to 80 years old with moderate to severe, newly diagnosed or relapsing PV or PF, with a clinical presentation and histopathology consistent with PV or PF.
* Positive circulating anti-desmoglein 1 (anti-dsg1) or 3 autoantibody titer.
* At screening, pemphigus disease area index score of at least 9 points for relapsing participants or at least 15 points for newly diagnosed participants.
* Adequate hematologic, hepatic, and renal function.
* Effective means of contraception.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Suspected paraneoplastic pemphigus and other forms of pemphigus that were not PV or PF.
* Previous use of a Bruton tyrosine kinase inhibitor.
* Pregnant or lactating women.
* Electrocardiogram clinically significant abnormalities.
* A history of malignancy of any type within 5 years before Day 1, other than surgically excised non-melanoma skin cancers or in situ cervical cancer.
* Use of immunologic response modifiers as concomitant medication and with the washout period.
* Use of proton pump inhibitor drugs such as omeprazole and esomeprazole within 3 days of Day 1.
* Concomitant use of known strong-to-moderate inducers or inhibitors of cytochrome P450 3A (CYP3A) within 3 days or 5 half-lives (whichever is longer) of Day 1
* Use of CYP3A-sensitive substrate drugs.
* Had received any investigational drug within the 30 days before Day 1.
* History of drug abuse within the previous 12 months.
* Alcoholism or excessive alcohol use.
* Any other clinically significant disease, condition or medical history that, in the opinion of the Investigator, would interfere with participant safety, trial evaluations, and/or trial procedures.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
8/01/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
17/12/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
131
Query!
Recruitment in Australia
Recruitment state(s)
WA
Query!
Recruitment hospital [1]
0
0
Central Recruiting (Principia Biopharma) - Fremantle
Query!
Recruitment hospital [2]
0
0
Central Recruiting (Principia Biopharma) - Melbourne
Query!
Recruitment hospital [3]
0
0
Central Recruiting (Principia Biopharma) - Sydney
Query!
Recruitment postcode(s) [1]
0
0
6160 - Fremantle
Query!
Recruitment postcode(s) [2]
0
0
3050 - Melbourne
Query!
Recruitment postcode(s) [3]
0
0
2217 - Sydney
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Florida
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Georgia
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Michigan
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Minnesota
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
New Mexico
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New York
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
North Carolina
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Ohio
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Texas
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Utah
Query!
Country [11]
0
0
Argentina
Query!
State/province [11]
0
0
Buenos Aires
Query!
Country [12]
0
0
Argentina
Query!
State/province [12]
0
0
San Nicolás
Query!
Country [13]
0
0
Brazil
Query!
State/province [13]
0
0
Campinas
Query!
Country [14]
0
0
Brazil
Query!
State/province [14]
0
0
Campo Grande
Query!
Country [15]
0
0
Brazil
Query!
State/province [15]
0
0
Ribeirão Preto
Query!
Country [16]
0
0
Bulgaria
Query!
State/province [16]
0
0
Pleven
Query!
Country [17]
0
0
Bulgaria
Query!
State/province [17]
0
0
Plovdiv
Query!
Country [18]
0
0
Bulgaria
Query!
State/province [18]
0
0
Sofia
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Manitoba
Query!
Country [20]
0
0
Croatia
Query!
State/province [20]
0
0
Osijek
Query!
Country [21]
0
0
Croatia
Query!
State/province [21]
0
0
Zagreb
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Bobigny
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Bordeaux
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Lille
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Pierre-Bénite
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Rouen
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Toulouse
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Berlin
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Dresden
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Düsseldorf
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Erlangen
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Heidelberg
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Kiel
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Lübeck
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Münster
Query!
Country [36]
0
0
Greece
Query!
State/province [36]
0
0
Athens
Query!
Country [37]
0
0
Greece
Query!
State/province [37]
0
0
Ioánnina
Query!
Country [38]
0
0
Greece
Query!
State/province [38]
0
0
Larisa
Query!
Country [39]
0
0
Greece
Query!
State/province [39]
0
0
Thessaloníki
Query!
Country [40]
0
0
Israel
Query!
State/province [40]
0
0
Be'er Sheva
Query!
Country [41]
0
0
Israel
Query!
State/province [41]
0
0
Haifa
Query!
Country [42]
0
0
Israel
Query!
State/province [42]
0
0
Ramat Gan
Query!
Country [43]
0
0
Israel
Query!
State/province [43]
0
0
Tel Aviv
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Brescia
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Catania
Query!
Country [46]
0
0
Italy
Query!
State/province [46]
0
0
Florence
Query!
Country [47]
0
0
Italy
Query!
State/province [47]
0
0
Milan
Query!
Country [48]
0
0
Italy
Query!
State/province [48]
0
0
Padova
Query!
Country [49]
0
0
Italy
Query!
State/province [49]
0
0
Parma
Query!
Country [50]
0
0
Italy
Query!
State/province [50]
0
0
Rome
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Torino
Query!
Country [52]
0
0
Poland
Query!
State/province [52]
0
0
Gdansk
Query!
Country [53]
0
0
Poland
Query!
State/province [53]
0
0
Kraków
Query!
Country [54]
0
0
Poland
Query!
State/province [54]
0
0
Lublin
Query!
Country [55]
0
0
Poland
Query!
State/province [55]
0
0
Warsaw
Query!
Country [56]
0
0
Poland
Query!
State/province [56]
0
0
Wroclaw
Query!
Country [57]
0
0
Serbia
Query!
State/province [57]
0
0
Belgrade
Query!
Country [58]
0
0
Serbia
Query!
State/province [58]
0
0
Novi Sad
Query!
Country [59]
0
0
Spain
Query!
State/province [59]
0
0
Barcelona
Query!
Country [60]
0
0
Spain
Query!
State/province [60]
0
0
Córdoba
Query!
Country [61]
0
0
Spain
Query!
State/province [61]
0
0
Madrid
Query!
Country [62]
0
0
Spain
Query!
State/province [62]
0
0
Pamplona
Query!
Country [63]
0
0
Taiwan
Query!
State/province [63]
0
0
Dalin
Query!
Country [64]
0
0
Taiwan
Query!
State/province [64]
0
0
Kaohsiung
Query!
Country [65]
0
0
Taiwan
Query!
State/province [65]
0
0
Taipei
Query!
Country [66]
0
0
Turkey
Query!
State/province [66]
0
0
Fatih
Query!
Country [67]
0
0
Turkey
Query!
State/province [67]
0
0
Istanbul
Query!
Country [68]
0
0
Turkey
Query!
State/province [68]
0
0
Konyaalti
Query!
Country [69]
0
0
Turkey
Query!
State/province [69]
0
0
Merkez
Query!
Country [70]
0
0
Ukraine
Query!
State/province [70]
0
0
Dnipro
Query!
Country [71]
0
0
Ukraine
Query!
State/province [71]
0
0
Kyiv
Query!
Country [72]
0
0
Ukraine
Query!
State/province [72]
0
0
Lviv
Query!
Country [73]
0
0
Ukraine
Query!
State/province [73]
0
0
Zaporizhzhya
Query!
Country [74]
0
0
United Kingdom
Query!
State/province [74]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Principia Biopharma, a Sanofi Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This was a Phase 3 randomized, parallel-group, double-blind, placebo-controlled trial (blinded treatment \[BT\] period) followed by an open-label extension \[OLE\] period intended to evaluate the efficacy and safety of oral PRN1008 in moderate to severe pemphigus. After completing the open-label extension period, eligible participants might continue in a long term extension (LTE) Period of 48 weeks.
Query!
Trial website
https://clinicaltrials.gov/study/NCT03762265
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Query!
When will data be available (start and end dates)?
Query!
Available to whom?
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/65/NCT03762265/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/65/NCT03762265/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT03762265